Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Withdrawn 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Kidney Neoplasms 1Carcinoma, Renal Cell 1

Interventions

Sunitinib 3Radiotherapy 3Cryosurgery 3pembrolizumab 2fludarabine phosphate 2Peripheral Blood Stem Cell Transplantation 2Nephrectomy 22-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid 2siltuximab 1avelumab 1Thalidomide 1Tacrolimus 1Suspensions 1Radiosurgery 1Radiofrequency Ablation 1Propranolol 1Powders 1PT-100 dipeptide 1Mycophenolic Acid 1Iodine 1Introns 1Interleukin-2 1Immunohistochemistry 1Genistein 1Gene Expression Profiling 1G250 monoclonal antibody 1Flow Cytometry 1Etoposide 1Docetaxel 1Cyclophosphamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Kidney Neoplasms × Iodine × Clear all
NCT01762592 2017-12-22

REDECT 2: REnal Masses: Pivotal Trial to DEteCT Clear Cell Renal Cell Carcinoma With PET/CT

Heidelberg Pharma AG

Phase 3 Withdrawn
Genitourinary

Carcinoma, Renal Cell, Kidney Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡